

# St George's Hospital UK Study of the use of recombinant factor VIIa in pelvic fracture and acetabular reconstruction

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/07/2009	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Michael Grounds

**Contact details**  
Adult Intensive Care Unit  
St James Wing  
St George's Hospital  
Blackshaw Road  
Tooting  
London  
United Kingdom  
SW17 0QT

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

N0236106542

## Study information

### Scientific Title

### Study objectives

This study will evaluate the possible effect of recombinant factor VIIa (rFVIIa) in the treatment of severe bleeding in severely injured trauma patients undergoing major orthopaedic reconstructive surgery.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Single centre randomised double-blind parallel group placebo-controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Surgery: Acetabular reconstruction

### Interventions

Use of recombinant factor VIIa in pelvic fracture and acetabular reconstruction

### Intervention Type

Drug

### Phase

Not Applicable

### Drug/device/biological/vaccine name(s)

Recombinant factor VIIa (rFVIIa)

**Primary outcome measure**

Total volume of perioperative blood loss

**Secondary outcome measures**

1. perioperative transfusion requirement (total volume of allogeneic blood components and salvaged RBC, total number of units of allogeneic blood components)
2. number of patients transfused with allogeneic blood components
3. total volume of crystalloid (Hartmann's solution, dextrose saline, normal saline) and colloid (succinylated gelatin) fluids infused
4. total operating time
5. time taken after entry to intensive care unit (ICU) or recovery unit to reach normal body temperature (36.337.1°C) and acidbase status (blood pH 7.357.45 with standard base excess 2 to +2)
6. time spent in ICU after surgery
7. days of hospitalization
8. number of times a patient was returned to the operating theatre

**Overall study start date**

01/06/2002

**Completion date**

31/03/2005

**Eligibility****Key inclusion criteria**

1. 1860 yr old
2. major pelvicaacetabular fracture caused by trauma
3. scheduled for semi-elective large reconstruction surgery with the potential of blood loss exceeding 50% of circulating blood volume

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

48

**Key exclusion criteria**

1. history of thrombosis (deep vein thrombosis, pulmonary embolism, cerebral thrombosis)
2. severe head injuries or an abnormal CT scan of the head due to head injuries
3. base deficit of greater than 15 mEq litre<sup>1</sup> or severe acidosis (pH<7.0.) before surgery

4. body weight exceeding 135 kg
5. known or suspected allergy to any drug that may be administered during the course of the study
6. cardiac arrest after trauma and before surgery at St George's Hospital
7. known congenital bleeding disorders
8. known pregnancy or positive pregnancy test at enrolment
9. previous participation in this study
10. previous receipt of rFVIIa within 48 h of screening
11. currently participating or having participated in another investigational drug study within the last 30 days

**Date of first enrolment**

01/06/2002

**Date of final enrolment**

31/03/2005

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre****Adult Intensive Care Unit**

London

United Kingdom

SW17 0QT

## Sponsor information

**Organisation**

Department of Health (UK)

**Sponsor details**

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

**Sponsor type**

Government

**Website**

http://www.doh.gov.uk

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

St George's Healthcare NHS Trust (UK)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2005		Yes	No